Novel Therapies for Aggressive B-Cell Lymphoma
Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially impr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/302570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565922259271680 |
|---|---|
| author | Kenneth A. Foon Kenichi Takeshita Pier L. Zinzani |
| author_facet | Kenneth A. Foon Kenichi Takeshita Pier L. Zinzani |
| author_sort | Kenneth A. Foon |
| collection | DOAJ |
| description | Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper. |
| format | Article |
| id | doaj-art-4fdc5ab5811f4b2ea075901dd90f938e |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-4fdc5ab5811f4b2ea075901dd90f938e2025-02-03T01:06:13ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/302570302570Novel Therapies for Aggressive B-Cell LymphomaKenneth A. Foon0Kenichi Takeshita1Pier L. Zinzani2Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USACelgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USADepartment of Hematology and Oncological Sciences “L. e A. Seràgnoli”, University of Bologna, Via Massarenti, 9-40138 Bologna, ItalyAggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.http://dx.doi.org/10.1155/2012/302570 |
| spellingShingle | Kenneth A. Foon Kenichi Takeshita Pier L. Zinzani Novel Therapies for Aggressive B-Cell Lymphoma Advances in Hematology |
| title | Novel Therapies for Aggressive B-Cell Lymphoma |
| title_full | Novel Therapies for Aggressive B-Cell Lymphoma |
| title_fullStr | Novel Therapies for Aggressive B-Cell Lymphoma |
| title_full_unstemmed | Novel Therapies for Aggressive B-Cell Lymphoma |
| title_short | Novel Therapies for Aggressive B-Cell Lymphoma |
| title_sort | novel therapies for aggressive b cell lymphoma |
| url | http://dx.doi.org/10.1155/2012/302570 |
| work_keys_str_mv | AT kennethafoon noveltherapiesforaggressivebcelllymphoma AT kenichitakeshita noveltherapiesforaggressivebcelllymphoma AT pierlzinzani noveltherapiesforaggressivebcelllymphoma |